Business
Queen's Award for Enterprise
Queen's Award for Enterprise.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 7154W Oxford BioDynamics PLC 23 April 2019 \n\n23 April 2019\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nOxford BioDynamics receives Queen's Award for Enterprise\n \n· The Queen's Award for Enterprise is the UK's highest accolade for business success\n· OBD honoured with the award for Enterprise in Innovation for its EpiSwitch™ platform\n \nOxford BioDynamics Plc is delighted to announce that it has today been recognised as a winner of the 2019 Queen's Award for Enterprise, the most prestigious enterprise award given to UK businesses. The Company has been granted the Queen's Award for Enterprise in Innovation, demonstrating the outstanding performance and commercial success of OBD's proprietary technology platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its functional links to patient stratifications and outcomes in oncology, neurodegenerative, inflammatory, metabolic and other indications.\n \nEpiSwitch™ is an innovative technology platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as \"chromosome conformation signatures\". These biomarker signatures can provide a compelling, stable framework from which changes in the regulation of a genome can be analysed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities.\n \nValidated EpiSwitch™ biomarker applications have demonstrated high efficacy in predictive, prognostic and diagnostic patient stratifications for lung, haematological, prostate, thyroid and skin cancers, as well as in rheumatoid arthritis, and amyotrophic lateral sclerosis. Baseline predictive stratifications by EpiSwitch™ for response to immune-checkpoint inhibitors are excellent surrogates for standard primary endpoints used in clinical trials, such as progression free survival. The Company has recently entered into its fifth collaboration agreement with a leading pharmaceutical company for the development of predictive biomarkers for immuno-oncology therapeutics. To date, EpiSwitch™ has been used to develop biomarkers on more than 6,500 blood samples in over 140 diverse projects.\n \nThe EpiSwitchTM ...